Full name
A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome
NCT Number
NCT04965636
Geography
US
Non-US
Locations
Argentina, Brazil, Israel, Netherlands, Turkey, United States
Primary Endpoints
Number of HES flares experienced by participants per year. Up to Week 52
External Link
https://clinicaltrials.gov/study/NCT04965636
Order
1
Disease
Version
Phase
3
Status
Active, not recruiting